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a meta-analysis of GWAS with > 2,500,000 imputed SNPs in Caucasian
women from four population-based cohorts: three cohorts from the Rotter-
dam Study (RS-I, RS-II, and RS-III) and the Erasmus Rucphen Family (ERF)
Study. Controls using analgesics were excluded. In total approximately 680
cases and 4180 controls were included in the meta-analysis. The program
METAL was used to perform the meta-analysis using an additive model. The
genomic control method was used to correct for any residual population
stratiﬁcation or relatedness not accounted for by the four most important
PCs (all lambda’s < 1.1).
Results: The average prevalence of CWP in the four studies was 15%. The
most signiﬁcant signal of the meta-analysis was at 4p15.3, in intron 1 of
Prominin 1 (PROM1), which reached borderline genome wide signiﬁcance
(p=5.5×10-8). The effect allele T (minor allele frequency = 6%) of the
most signiﬁcant SNP gives a consistent higher risk for CWP in all four
cohorts examined (meta-analysis OR per T-allele: 1.74, 95% CI: 1.43-2.14,
p=5.5×10-8). As observed from RS-I data, the effect allele also gives a
higher risk for joint speciﬁc pain in hip (p = 0.024, OR: 1.34, 95% CI:
1.03-1.71), hand (p=0.021, OR: 1.31, 95% CI: 1.04-1.65), and low back and
neck (p=0.001, OR: 1.43, 95% CI: 1.16-1.76). The PROM1 gene encodes a
pentaspan transmembrane glycoprotein, for which no link with CWP has
been established yet.
Conclusions: This large GWAS meta-analysis on CWP shows a strongly
suggestive association for CWP in women at chr4p15.3, just escap-
ing genome-wide signiﬁcance. Therefore, replication in other cohorts is
needed, which might unveil further loci for CWP.
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Purpose: To clarify the role of common genetic variation in the Interleukin-
1β (IL1B) and Interleukin-1R antagonist (IL1RN) genes on risk of prevalence
of knee and hip osteoarthritis (OA) and severity of knee OA by means of
large-scale meta-analyses.
Methods: We searched PubMed for articles assessing the role of IL1B and
IL1RN polymorphisms and haplotypes on the risk of hip and/or knee OA.
Novel data was included from 8 additional studies. A meta-analysis was
performed using ﬁxed- and random-effects models, including all available
data with allele/genotype counts, with a total of 3676 hip OA and 5128
knee OA cases, and 6559 and 9132 controls respectively. The role of ILRN
haplotypes on radiographic severity of knee OA, previously reported, was
tested in 1918 cases with Kellgren-Lawrence (K/L) 1 or 2 compared to 199
cases with K/L 3 or 4.
Results: The meta-analysis showed no evidence of association between
common genetic variation in the IL1B or IL1RN genes and risk of hip
OA or knee OA (P>0.05 for rs16944, rs1143634, rs419598 and haplotype
C-G-C (rs1143634, rs16944 and rs419598) previously implicated in risk of
hip OA). The C-T-A haplotype formed by rs419598, rs315952 and rs9005,
previously implicated in radiographic severity of knee OA, was associated
with reduced severity of knee OA (OR=0.71 95%CI 0.56-0.91; P=0.006,
I2=74%), but did not achieve statistical signiﬁcance in a random effects
model (OR=0.61 95%CI 0.35-1.06 P=0.08).
Conclusions: Common genetic variation in the Interleukin-1 region is not
associated with prevalence of hip or knee OA but may be associated with
severity of knee OA.
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Purpose: Osteoarthritis (OA), the most common form of arthritis, is a mul-
tifactorial disease thought to be caused by complex interplay between envi-
ronmental and genetic factors. The genetic architecture of OA has not been
characterised yet; as with many common complex traits it appears to be
of a highly polygenic nature with multiple risk loci conferring small effects,
detection of which necessitates studies in sets of large sample sizes. In order
to enable a well-powered genome-wide association study (GWAS) for OA,
we have formed the arcOGEN Consortium, a UK-wide collaboration aiming
to carry out a genome-wide scan of 8,000 OA cases in a 2-stage GWAS.
Methods: We have completed stage 1 GWAS in 3,177 knee and/or hip OA
cases, genotyped on the Illumina Human610 chip and have compared their
genotypes against 4,894 publicly available population-based UK controls
from the Wellcome Trust Case Control Consortium 2 (WTCCC2) study,
genotyped on the Illumina 1.2M platform.
Results: Of the 514,898 single nucleotide polymorphisms (SNPs) that
passed our quality control, 90 SNPs reached p values < 0.0001 (as op-
posed to 51 expected under the null hypothesis of no association). We
took forward 102 independent (r2<0.4) SNPs with p<0.0001 to in silico
replication in three further OA GWAS (from the deCODE, Framingham and
Rotterdam studies) and a subset of 52 SNPs in a UK-based GWAS (Twins
UK) comprising a total of 41,075 individuals. Based on meta-analysis results
across the arcOGEN and in silico replication datasets we prioritised 36 SNPs
for de novo replication in a further set of 6,255 OA cases and 8,289 controls
of European ancestry (from Spain, Greece, USA and the Netherlands). None
of the followed-up signals reached genome-wide signiﬁcance (p<5×10-8),
but this could be due to low power caused by limited sample size, small
effect sizes and phenotype heterogeneity. In the knee and/or hip OA
meta-analysis across the discovery and replication sets, the strongest signal
was observed for rs2277831, which lies within the MICAL3 gene (odds
ratio for the G allele (OR) 1.07 [1.04-1.11], p=2.85×10-5). We also examined
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hip- and knee-speciﬁc OA but none of the signals reached genome-wide
signiﬁcance, as expected given the smaller sample sizes.
Conclusions: Our study highlights possible novel OA susceptibility loci,
which will require corroboration in sample sets of larger size. Stage 2
of the arcOGEN GWAS, which involves the collection and genome-wide
scanning of an independent set of at least 4,500 OA cases (deﬁned by the
severe endpoint of total hip and/or total knee replacement), is currently
underway. A combined analysis of the 2-stage GWAS including up to 8,000
cases will provide us with suﬃcient power (90% power to detect an allele
with frequency 0.20 and allelic OR of 1.2) to detect modest effects at
common loci at the genome-wide signiﬁcance level.
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Purpose: Osteoarthritis (OA) is a complex disease of the joint, characterized
by progressive degradation of the cartilage matrix by aggrecanases and
collagenases. Nitric oxide (NO), the product of inducible nitric oxide syn-
thase (iNOS), not only suppresses the synthesis of cartilage matrix, but also
increases expression of proteases in OA. Although iNOS is readily inducible
in almost all rodent cell types in culture, in contrast, normal human cells
are recalcitrant to induction with cytokines due to epigenetic silencing by
DNA methylation. It has been shown that transcriptional activation of the
human iNOS gene requires the presence of cytokine-responsive elements
upstream of -3.8 kb in the 5’-ﬂanking region of the human iNOS gene.
However, it is not known whether the activation of iNOS in OA chon-
drocytes can be attributed to epigenetic “unsilencing”with implications for
therapeutic intervention in OA.
Objective: To examine and correlate mRNA expression of iNOS with the
DNA methylation status of speciﬁc CpG sites in the iNOS promoter and NF-
?B enhancer elements regions, and to examine if the increased expression
of iNOS in OA chondrocytes is attributable to loss of DNA methylation.
Methods: Control chondrocytes were obtained from human fetal femurs
(7-11wpc) or from fracture neck of femur (#NOF) patients; the latter
patients typically suffer from osteoporosis, which does not affect the
cartilage. #NOF patients are widely used as a suitable non-OA control. OA
chondrocytes were isolated from the femoral heads of patients undergoing
hip replacement surgery due to OA. Genomic DNA and total RNA were
extracted simultaneously. Expression of iNOS was quantiﬁed by qPCR and
the DNA methylation status of the iNOS promoter and enhancer regions
was determined by bisulﬁte modiﬁcation, followed either by cloning and
sequencing or pyrosequencer analysis to quantify percentage methylation.
Results: OA samples showed a 13-fold increase in iNOS expression com-
pared to #NOF samples (n=14, P<0.05). NOF# samples (n=14) showed a
79-fold increase in iNOS expression relative to fetal cells (P<0.01) and OA
samples showed a 2747-fold increase in iNOS expression compared to fetal
samples (n=14, P<0.01). The iNOS promoter has only 7 CpG sites in over
1000bp, 6 of which were highly methylated in both controls and OA. The
CpG site at -289 was un-methylated in both groups. The sites in the coding
region (+13, +33 and +38), were largely unmethylated in #NOF and OA
patients, although hyper-methylated in the fetal samples.
Two NF-?B enhancer elements regions were analyzed, the enhancer region
at -5.2 was found to be totally unmethylated in all samples (<10%);
however, the enhancer region at -5.8 was signiﬁcantly de-methylated
in OA samples (n=12, P<0.05) compared with #NOF samples, with an
approximate 10% loss of methylation.
Conclusions: These studies indicate the CpG sites in the proximal coding
region may be involved in epigenetic regulation of iNOS. However, upreg-
ulation of iNOS in OA chondrocytes is not a consequence of epigenetic
unsilencing in this region, because these sites are un-methylated even in
#NOF chondrocytes. De-methylation of -5.8 enhancer element region may
be an important factor for iNOS overexpression in OA chondrocytes and,
our studies demonstrate that the regulation of iNOS expression in OA
chondrocytes appears to be the result of multiple epigenetic modiﬁcations
in different physiologic conditions. Further understanding of the regulation
and epigenetic modulation of iNOS will inform our understanding the
pathogenesis of OA.
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Purpose: Frizzled related protein (FRZB/sFRP3) is a secreted WNT antago-
nist isolated from articular cartilage and expressed in developing skeletal
elements. Polymorphisms in the human FRZB gene are associated with
susceptibility for osteoarthritis. Induction of experimental osteoarthritis
in Frzb-/- mice results in enhanced cartilage degradation associated with
increased Wnt signalling, Mmp3 expression, Mmp activity and cortical bone
thickness. In this study we used a whole mouse genome micro-array to
investigate differentially regulated pathways between wild-type and Frzb-/-
mice in tibial articular cartilage.
Methods: Articular cartilage from the tibia was isolated from 6 weeks
old Frzb-/- mice and wild-type littermates. RNA was isolated using the
RNeasy Fibrous tissue mini kit (Qiagen). RNA quality was assessed using an
Agilent 2100 Bio-analyzer and RNA nanochips (Agilent technologies Inc).
The transcriptional proﬁles were analysed by the VIB MicroArrays Facility
using the whole genome Affymetrix GeneChip® Mouse Genome 430 2.0
Array. Articular cartilage from one tibia from 3 wild-type mice and 2 Frzb-/-
mice was used (3 vs. 2 chips comparison). Gene expression analysis was
based on the RMA expression values and the MAS 5.0 detection calls.
PANTHER Classiﬁcation System software, DAVID Bioinformatics resources
and FUNNET transcriptional analysis were used for pathway analysis.
Results: Using Benjamini-Hochberg corrected P-values (p < 0,01) in com-
bination with a cut-off fold change |log2-ratio|>1 the analysis showed
that 697 transcripts were signiﬁcantly upregulated in the Frzb-/- sample
group. PANTHER pathway analysis identiﬁed overrepresentation of genes
linked to the Integrin, Wnt and Cadherin signalling pathways (corrected
p-values 3×10-9, 5×10-5 and 5×10-3 respectively). Not surprisingly, genes
linked to skeletal development and extracellular matrix were enriched in
the analysis. DAVID analysis similarly identiﬁed the Wnt and Integrin path-
ways but also EGF signalling. FUNNET identiﬁed both Wnt and TGF/BMP
signalling. For the Wnt signalling pathway different Frizzled receptors,
Wnt9a ligand and distinct intracellular and extracellular antagonists were
upregulated suggesting compensatory mechanisms in the absence of Frzb.
In addition, upregulation of bone morphogenetic protein and other trans-
forming growth factor beta superfamily members and receptors suggests
compensatory upregulation of this pathway. The link with integrin upreg-
ulation further supports our earlier data that identiﬁed a role for Frzb in
mechanobiology.
Conclusions: In this study we demonstrated that loss of Frzb results in
the upregulation of the Wnt signalling pathway and a possible compen-
satory upregulation of BMP signalling. The upregulation of the Integrin
and Cadherin signalling pathway suggest an important role for Frzb in the
interactions of cells with surrounding cells and extracellular matrix.
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Purpose: To assess heritability of clinical and radiographic features of hand
osteoarthritis (OA) in affected patients and their siblings.
Methods: As part of an ongoing genetic study (GHOST-Genetics of Hand
Osteoarthritis Study), patients with hand osteoarthritis were recruited for
a family-based study aimed at assessing genetic determinants of hand OA.
A convenience sample of unrelated patients with symptomatic (i.e. pain or
disability), idiopathic, clinical and radiographic hand OA and their siblings
were evaluated by examination, and radiography. For inclusion, probands
must have been ≥45 years of age, met American College of Rheumatology
clinical classiﬁcation criteria for hand OA and have radiographic evidence
of OA in the form of osteophytes in either ﬁrst metacarpal (1st CMC)
joint or at least 2 distal interphalangeal (DIP) or proximal interphalangeal
(PIP) joints. Radiographs were scored for hand OA features by radiographic
atlas. The heritability of hand OA phenotypes was assessed for overall
